×

Engineered Immune Cell Therapy Discovery and Development

About Creative Biolabs

We help research teams translate ambitious ideas in engineered immunity into clear, executable development programs—from discovery and design to translational evaluation and development readiness.

Who We Are

A research partner for engineered immune cell therapy innovation

Creative Biolabs is a biotechnology research and development partner specializing in engineered immune cell therapy discovery, engineering, evaluation and development support. We work closely with biotechnology, pharmaceutical and academic teams to address scientific and technical challenges across CAR-T, CAR-NK, TCR-T, TIL and other immune cell modalities, alongside cancer vaccine development, receptor engineering, cell engineering, delivery strategies, functional evaluation and translational readiness.

Our role extends beyond delivering isolated services. We build application-driven, mechanism-aware workflows around the realities of each program—connecting target and binder strategy, receptor and vector design, cell engineering, in vitro and in vivo evaluation, process development and decision-ready reporting from early concept validation through preclinical-stage planning.

Our Expertise

One partner across an expanding immune cell therapy landscape

Our multidisciplinary teams connect target biology, receptor design, cell engineering, cellular function, translational evidence and development planning—so every work package contributes to the larger program.

Integrated cellular therapy research and development
Focused scientific questions become connected, decision-ready development programs.
01 / ENGINEERED IMMUNITY

CAR- and TCR-engineered therapies

From biomarker and binder strategy through construct design, gene delivery and functional characterization.

Explore CAR-T development
02 / CELL MODALITIES

Beyond conventional T cells

CAR-NK, CAR-MA, TIL, CIK, CAR-Treg, CAR-B, CAR-monocyte and other cell-based strategies.

Discover CAR-NK capabilities
03 / IMMUNE DISCOVERY

Cancer vaccines and immune research

Antigen and epitope research, vaccine engineering, characterization and in vivo assessment.

Explore vaccine development
04 / NEXT GENERATION

Advanced engineering strategies

Allogeneic development, CRISPR editing, mRNA and LNP delivery, logic-gated designs and direct in vivo engineering.

Explore in vivo development
05 / TRANSLATION

Functional and safety evaluation

Custom in vitro assays, relevant models and studies addressing efficacy, specificity, persistence and toxicity.

Explore functional development
06 / READINESS

Development and manufacturing support

Process and analytical development plus plasmid, viral vector, IVT RNA, LNP and engineered cell capabilities.

Explore CDMO capabilities

Development Continuum

A connected path from biological question to development decision

Engage us for a focused study or a coordinated program. Each phase can stand alone or connect with adjacent workstreams to keep methods, data and decision criteria aligned.

01

Discover

Targets, biomarkers, antigens, epitopes, binders, TCRs and feasibility strategy.

02

Engineer

Construct design, sequence optimization, vectors, delivery and cellular engineering.

03

Evaluate

In vitro potency and phenotype studies with fit-for-purpose in vivo models.

04

Translate

Mechanistic studies, biomarkers, immune monitoring and safety-oriented evidence.

05

Advance

Process, analytics, manufacturing preparation and support for later development milestones.

Scope, quality level, documentation and regulatory relevance are defined for each project according to its intended use and stage of development.

Technology Platforms

Purpose-built technologies for harder development questions

Our platform portfolio gives teams multiple ways to interrogate target biology, engineer cellular function and generate evidence that supports the next decision.

CE

Cell engineering and receptor design

CellRapeutics™ CAR and TCR technologies, CRISPR-edited cells, mRNA engineering, stable packaging cell lines and bispecific strategies.

View engineering platforms →
HD

High-dimensional discovery

T-Scan, Surfarray™ cell microarrays, Tseeking™ TCR/ligand discovery and display-based approaches for high-throughput interrogation.

Explore discovery technologies →
TE

Translational evaluation

Animal models, organoids, trial-on-chip and immune monitoring for efficacy, persistence, safety and mechanism studies.

Explore translational models →
ME

Manufacturing enablement

Connected process and analytical development for plasmids, viral vectors, IVT RNA, LNPs and engineered cells.

Explore process development →

How We Work

A practical collaboration built around your next decision

We translate the scientific objective into a transparent work plan, then keep methods, milestones and outputs connected to the evidence your team needs.

Collaborative planning for engineered immune cell therapy development
01

Define the question

We align on the biology, development stage, intended use, constraints and criteria for a meaningful result.

02

Design the evidence plan

We shape fit-for-purpose work packages with appropriate controls, decision points, deliverables and reporting expectations.

03

Execute with specialist teams

Established platforms and custom methods are selected according to the modality, scientific risk and stage of the program.

04

Turn results into a decision

Data and technical interpretation are organized to support the next experiment, candidate choice or development path.

Why Creative Biolabs

Breadth when you need options. Depth when the program gets specific.

Building on two decades of biotechnology experience, we support global biopharma, biotechnology and academic teams with flexible, scientifically grounded collaboration.

01

One scientific conversation

Coordinate adjacent disciplines through one program view without rebuilding context across disconnected vendors.

02

Flexible entry points

Begin with one assay, a focused work package or an integrated plan, then expand when the evidence supports it.

03

Modality-aware strategy

Select technologies according to the target, cell type, construct, delivery route and development stage.

04

Decision-oriented execution

Connect study design, controls, milestones and reporting to the decisions that move a program forward.

Global Collaboration

Trusted by Global Leaders

Creative Biolabs supports biotechnology, pharmaceutical and academic research teams worldwide with responsive scientific communication and flexible program design.

AbbVie
Amgen
AstraZeneca
Bristol Myers Squibb
Broad Institute
Eli Lilly and Company
GSK
Johnson and Johnson
Novartis
Pfizer

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Receive our latest news and insights.